DNA methylation status is more reliable than gene expression at detecting cancer in prostate biopsy

British Journal of Cancer

Volumn 111, Issue 4, 2014, Pages 781-789

  Paziewska, A ^a   Dabrowska, M ^b   Goryca, K ^b   Antoniewicz, A ^c   Dobruch, J ^a   Mikula, M ^b   Jarosz, D ^a,b   Zapala, L ^c   Borowka, A ^a   Ostrowski, J ^a,b  

^a MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c Multidisciplinary Hospital Warsaw Miedzylesie   (Poland)

Author keywords

450K Infinium Methylation BeadChip; biomarker; DNA methylation; gene expression; prostate cancer

Indexed keywords

MESSENGER RNA; TUMOR MARKER;

AMACR GENE; APC GENE; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DGKZ GENE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DNA METHYLATION; DNA METHYLATION ASSAY; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC MARKER; HES5 GENE; HOXC6 GENE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MALE; MICROARRAY ANALYSIS; MULTIPLEX POLYMERASE CHAIN REACTION; NEEDLE BIOPSY; NUCLEOTIDE SEQUENCE; PCA3 GENE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE BIOPSY; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROSTATECTOMY; RARB GENE; RELIABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TACC2 GENE;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ADULT; AGED; AGED, 80 AND OVER; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BIOPSY; CARRIER PROTEINS; DIACYLGLYCEROL KINASE; DNA METHYLATION; HUMANS; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, RETINOIC ACID; REPRESSOR PROTEINS; ROC CURVE; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84906087876     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.337     Document Type: Article

References (50)

1. Altintas DM, Allioli N, Decaussin M, de Bernard S, Ruffion A, Samarut J, Vlaeminck-Guillem V (2013) Differentially expressed androgen-regulated genes in androgen-sensitive tissues reveal potential biomarkers of early prostate cancer. PLoS One 8: e66278.
2. Anastasiadis A, Zapaa L, Cordeiro E, Antoniewicz A, Dimitriadis G, De Reijke T (2013) Complications of prostate biopsy. Expert Rev Anticancer Ther 13: 829-837.
3. Babaian RJ, Toi A, Kamoi K, Troncoso P, Sweet J, Evans R, Johnston D, Chen M (2000) A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol 163: 152-157.
4. Bhavsar T, McCue P, Birbe R (2013) Molecular diagnosis of prostate cancer: are we up to age? Semin Oncol 40: 259-275.
5. Bradford TJ, Tomlins SA, Wang X, Chinnaiyan AM (2006) Molecular markers of prostate cancer. Urol Oncol 24: 538-551.
6. Chen Y, Li J, Yu X, Li S, Zhang X, Mo Z, Hu Y (2013) APC gene hypermethylation and prostate cancer: a systematic review and meta-analysis. Eur J Hum Genet 21: 929-935.
7. Day TK, Bianco-Miotto T (2013) Common gene pathways and families altered by DNA methylation in breast and prostate cancers. Endocr Relat Cancer 20: R215-R232.
8. Didkowska J, Wojciechowska U, Zatonski W (2012) Cancer in Poland in 2011. Warsaw: National Cancer Registry. Available at: http://onkologia.org.pl/wp- content/uploads/COI-Nowotwory2013-web.pdf.
9. Eskicorapci SY, Guliyev F, Akdogan B, Dogan HS, Ergen A, Ozen H (2005) Individualization of the biopsy protocol according to the prostate gland volume for prostate cancer detection. J Urol 173: 1536-1540.
10. Fink KG, Hutarew G, Lumper W, Jungwirth A, Dietze O, Schmeller NT (2001) Prostate cancer detection with two sets of ten-core compared with two sets of sextant biopsies. Urology 58: 735-739.
11. Florl AR, Steinhoff C, Müller M, Seifert H-H, Hader C, Engers R, Ackermann R, Schulz WA (2004) Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br J Cancer 91: 985-994.
12. Gaudin PB, Reuter VE (1997) Benign mimics of prostatic adenocarcinoma on needle biopsy. Anat Pathol 2: 111-134.
13. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JYH, Zhang J (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5: R80.
14. Goering W, Kloth M, Schulz WA (2012) DNA methylation changes in prostate cancer. Methods Mol Biol 863: 47-66.
15. Hessels D, Verhaegh GW, Schalken JA, Witjes JA (2004) Applicability of biomarkers in the early diagnosis of prostate cancer. Expert Rev Mol Diagn 4: 513-526.
16. Hodge KK, McNeal JE, Terris MK, Stamey TA (1989) Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 142: 71-74 (discussion 74-75).
17. Hsu M-J, Chang Y-CI, Hsueh H-M (2014) Biomarker selection for medical diagnosis using the partial area under the ROC curve. BMC Res Notes 7: 25.
18. Javed S, Langley SEM (2013) Importance of HOX genes in normal prostate gland formation, prostate cancer development and its early detection. BJU Int 113: 535-540.
19. Jerónimo C, Bastian PJ, Bjartell A, Carbone GM, Catto JWF, Clark SJ, Henrique R, Nelson WG, Shariat SF (2011) Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol 60: 753-766.
20. Jones JS, Patel A, Schoenfield L, Rabets JC, Zippe CD, Magi-Galluzzi C (2006) Saturation technique does not improve cancer detection as an initial prostate biopsy strategy. J Urol 175: 485-488.
21. Kim JH, Dhanasekaran SM, Prensner JR, Cao X, Robinson D, Kalyana-Sundaram S, Huang C, Shankar S, Jing X, Iyer M, Hu M, Sam L, Grasso C, Maher CA, Palanisamy N, Mehra R, Kominsky HD, Siddiqui J, Yu J, Qin ZS, Chinnaiyan AM (2011a) Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Res 21: 1028-1041.
22. Kim JW, Kim S-T, Turner AR, Young T, Smith S, Liu W, Lindberg J, Egevad L, Gronberg H, Isaacs WB, Xu J (2012) Identification of new differentially methylated genes that have potential functional consequences in prostate cancer. PLoS One 7: e48455.
23. Kim Y-J, Yoon H-Y, Kim S-K, Kim Y-W, Kim E-J, Kim IY, Kim W-J (2011b) EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling. Clin Cancer Res 17: 4523-4530.
24. Kron K, Pethe V, Briollais L, Sadikovic B, Ozcelik H, Sunderji A, Venkateswaran V, Pinthus J, Fleshner N, van der Kwast T, Bapat B (2009) Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays. PLoS One 4: e4830.
25. Lasko TA, Bhagwat JG, Zou KH, Ohno-Machado L (2005) The use of receiver operating characteristic curves in biomedical informatics. J Biomed Inform 38: 404-415.
26. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
27. Lucas SM, Heath EI (2012) Current challenges in development of differentially expressed and prognostic prostate cancer biomarkers. Prostate Cancer 2012: 640968.
28. Al-Maghrebi M, Kehinde EO, Anim JT, Sheikh M (2012) The role of combined measurement of tissue mRNA levels of AMACR and survivin in the diagnosis and risk stratification of patients with suspected prostate cancer. Int Urol Nephrol 44: 1681-1689.
29. McCabe CD, Spyropoulos DD, Martin D, Moreno CS (2008) Genome-wide analysis of the homeobox C6 transcriptional network in prostate cancer. Cancer Res 68: 1988-1996.
30. Mikula M, Rubel T, Karczmarski J, Goryca K, Dadlez M, Ostrowski J (2011) Integrating proteomic and transcriptomic high-throughput surveys for search of new biomarkers of colon tumors. Funct Integr Genomics 11: 215-224.
31. Neves AF, Araújo TG, WKFS Biase, Meola J, Alcântara TM, Freitas DG, Goulart LR (2008) Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis. Clin Biochem 41: 1191-1198.
32. Pepe P, Aragona F (2007) Saturation prostate needle biopsy and prostate cancer detection at initial and repeat evaluation. Urology 70: 1131-1135.
33. Rabets JC, Jones JS, Patel A, Zippe CD (2004) Prostate cancer detection with office based saturation biopsy in a repeat biopsy population. J Urol 172: 94-97.
34. Ravery V, Dominique S, Panhard X, Toublanc M, Boccon-Gibod L, Boccon-Gibod L (2008) The 20-core prostate biopsy protocol-a new gold standard? J Urol 179: 504-507.
35. Rittenhouse H, Blase A, Shamel B, Schalken J, Groskopf J (2013) The long and winding road to FDA approval of a novel prostate cancer test: our story. Clin Chem 59: 32-34.
36. Rouprêt M, Hupertan V, Yates DR, Catto JWF, Rehman I, Meuth M, Ricci S, Lacave R, Cancel-Tassin G, de la Taille A, Rozet F, Cathelineau X, Vallancien G, Hamdy FC, Cussenot O (2007) Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin Cancer Res 13: 1720-1725.
37. Scattoni V, Raber M, Abdollah F, Roscigno M, Dehò F, Angiolilli D, Maccagnano C, Gallina A, Capitanio U, Freschi M, Doglioni C, Rigatti P, Montorsi F (2010) Biopsy schemes with the fewest cores for detecting 95% of the prostate cancers detected by a 24-core biopsy. Eur Urol 57: 1-8.
38. Scattoni V, Roscigno M, Raber M, Dehò F, Maga T, Zanoni M, Riva M, Sangalli M, Nava L, Mazzoccoli B, Freschi M, Guazzoni G, Rigatti P, Montorsi F (2008) Initial extended transrectal prostate biopsy-are more prostate cancers detected with 18 cores than with 12 cores? J Urol 179: 1327-1331 (discussion 1331).
39. Serefoglu EC, Altinova S, Ugras NS, Akincioglu E, Asil E, Balbay MD (2013) How reliable is 12-core prostate biopsy procedure in the detection of prostate cancer? Can Urol Assoc J 7: E293-E298.
40. Skrzypczak M, Goryca K, Rubel T, Paziewska A, Mikula M, Jarosz D, Pachlewski J, Oledzki J, Ostrowski J (2010) Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability. PLoS One 5: e13091.
41. Sørensen KD, Ørntoft TF (2010) Discovery of prostate cancer biomarkers by microarray gene expression profiling. Expert Rev Mol Diagn 10: 49-64.
42. Svetec D, McCabe K, Peretsman S, Klein E, Levin H, Optenberg S, Thompson I (1998) Prostate rebiopsy is a poor surrogate of treatment efficacy in localized prostate cancer. J Urol 159: 1606-1608.
43. Teschendorff AE, Marabita F, Lechner M, Bartlett T, Tegner J, Gomez-Cabrero D, Beck S (2013) A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data. Bioinformatics 29: 189-196.
44. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034.
45. Vashi AR, Wojno KJ, Gillespie B, Oesterling JE (1998) A model for the number of cores per prostate biopsy based on patient age and prostate gland volume. J Urol 159: 920-924.
46. Vinarskaja A, Yamanaka M, Ingenwerth M, Schulz WA (2011) DNA Methylation and the HOXC6 Paradox in Prostate Cancer. Cancers (Basel) 3: 3714-3725.
47. Wang X, Spandidos A, Wang H, Seed B (2011) PrimerBank: a PCR primer database for quantitative gene expression analysis, 2012 update. Nucleic Acids Res 40: D1144-D1149.
48. Warren JD, Xiong W, Bunker AM, Vaughn CP, Furtado LV, Roberts WL, Fang JC, Samowitz WS, Heichman KA (2011) Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Medicine 9: 133.
49. Willard SS, Koochekpour S (2012) Regulators of gene expression as biomarkers for prostate cancer. Am J Cancer Res 2: 620-657.
50. Yang B, Bhusari S, Kueck J, Weeratunga P, Wagner J, Leverson G, Huang W, Jarrard DF (2013) Methylation profiling defines an extensive field defect in histologically normal prostate tissues associated with prostate cancer. Neoplasia 15: 399-408.